When is it time to add a GLP-1 RA in type 2 diabetes? The often overlapping conditions of type 2 diabetes (T2D), obesity, chronic kidney disease (CKD), and cardiovascular disease (CVD) continue to strain Australia's healthcare system. With these conditions sharing common pathways and risks, and around 40% of T2D patients developing CKD, integrated, proactive management is crucial. For GPs, managing chronic diseases can be challenging. Many patients using SGLT-2 inhibitors for kidney or heart protection still face suboptimal glycaemic control, with HbA1c levels above target. Studies show that up to one-third of these patients require additional glucose-lowering treatment within 6-12 months. Even when SGLT-2 inhibitors are prescribed for cardiorenal protection, maintaining optimal glycaemic control is essential. GPs often face uncertainty about the next steps when HbA1c remains elevated despite SGLT-2i therapy. Questions arise regarding additional glucose-lowering agents, balancing clinical priorities, and navigating the Pharmaceutical Benefits Scheme (PBS). Experts have labeled GLP-1 RAs as a potential fourth pillar of therapy for diabetes-associated kidney disease, alongside RAAS inhibitors, SGLT-2is, and finerenone. GLP-1 RAs improve glycaemic control and offer cardiovascular and kidney protection in clinical studies. Their benefits extend beyond glucose lowering, promoting weight loss and improving metabolic health, which are crucial for disease progression in T2D and CKD. The decision to introduce a GLP-1 RA should consider Therapeutic Goods Administration (TGA) indications, estimated glomerular filtration rate (eGFR), albuminuria, cardiovascular comorbidities, and obesity. For patients already on SGLT-2i, combining the two therapies may provide complementary benefits. Semaglutide, now approved in Australia, carries a new indication to reduce the risk of sustained kidney function decline and cardiovascular death in adults with T2D and CKD. This expanded indication highlights GLP-1 RAs' growing role in integrated diabetes care, beyond glucose management. GLP-1 RAs are generally well-tolerated, but gastrointestinal side effects like nausea and vomiting are common initially and typically diminish over time. Understanding TGA and PBS indications and documentation requirements is vital for timely patient access. Education and support around these evolving pathways will empower confident prescribing in general practice. However, current PBS restrictions do not support co-prescribing SGLT-2i and GLP-1 RAs unless the SGLT-2i is used for renal or heart failure indications. As diabetes management complexity increases, GPs play a crucial role in bridging the gap between evidence and practice. Awareness of evolving therapeutic options, including when to introduce GLP-1 RAs alongside SGLT-2is, is essential to improve outcomes for hundreds of thousands of Australians with T2D and its complications.
